VXRT · Vaxart, Inc. · Webcasts, Transcripts & Audio
$0.32
+0.00 (+0.00%)
At close · Jul 8
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In the second quarter of 2026, management concluded that our cash, cash equivalents and investments are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our financial statements, and these conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$126.27M
Shares
243.70M
Volume · Jul 8
11.57M
Avg daily vol (3M)
4.77M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Vaxart, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Vaxart, Inc. (VXRT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Annual General Meeting
Investor event
2026-11-06
Vaxart, Inc. (VXRT) November 6, 2026 Annual General Meeting
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
Vaxart, Inc. (VXRT) Q3 2026 Earnings Call
Revenue
$10.62M
▼ 85.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Vaxart, Inc. (VXRT) September 14, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call
Revenue
$27.18M
▼ 31.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-08
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call
Revenue
$39.23M
▲ 87.9% YoY Diluted EPS
$0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-03-13
Vaxart, Inc. (VXRT) March 13, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-12
Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript
Positive tone
Phase 2b COVID-19 sentinel cohort data
Dynavax/Sanofi COVID-19 partnership
Oral norovirus vaccine (lactating mothers data)
Revenue
$104.24M*
▲ 586.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Annual General Meeting
Investor event
2025-11-18
Vaxart, Inc. (VXRT) November 18, 2025 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-13
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Confident tone
COVID market opportunity and strain adaptability
Dynavax partnership / business development
Norovirus program and partnership search
Revenue
$72.41M
▲ 1367.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
Positive tone
Norovirus program
COVID-19 Phase IIb trial / BARDA stop work order
Partnering and business development
Revenue
$39.73M
▲ 520.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
Balanced tone
Norovirus vaccine program
COVID-19 Phase 2b trial restart
Reverse stock split and NASDAQ compliance
Revenue
$20.88M
▲ 857.2% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript
Balanced tone
Norovirus Program
COVID-19 Program / Stop Work Order
Government and Regulatory Engagement
Revenue
$15.19M*
▲ 368% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
Positive tone
Norovirus program
Regulatory engagement with FDA
Early-stage pipeline (HPV, flu, avian flu)
Revenue
$4.93M
▲ 134.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
Confident tone
Phase 2b COVID oral pill trial
Norovirus program
BARDA / Project NextGen COVID funding
Revenue
$6.40M
▲ 371.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
Positive tone
COVID-19 Phase IIb trial and Project NextGen
Norovirus vaccine in lactating mothers
New CEO leadership and execution
Revenue
$2.18M
▲ 223.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
Confident tone
COVID-19 oral vaccine program
Norovirus program
Leadership transition
Revenue
$3.25M*
▲ 14650% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript
Revenue
$2.10M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Vaxart, Inc. (VXRT) Q2 2023 Earnings Call Transcript
Revenue
$1.36M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Vaxart, Inc. (VXRT) Q1 2023 Earnings Call Transcript
Revenue
$675,000
▲ 694.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript
Revenue
$22,000*
▼ 70.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Vaxart, Inc. (VXRT) Q3 2022 Earnings Call Transcript
Revenue
$0
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Vaxart, Inc. (VXRT) Q2 2022 Earnings Call Transcript
Revenue
$0
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 webcasts